36703-88-5 Usage
Description
ISOPRINOSINE (also known as inosine pranobex) an antiviral drug combing of inosine and dimepranol acedoben (a salt of acetamidobenzoic acid and dimethylaminoisopropanol) in a ratio of 1 to 3. It is mainly used for treating the rare measles complication subacute sclerosing panencephalitis in conjunction with intrathecal interferon therapy1,2. In UK, it is also indicated for mucocutaneous infections due to herpes simplex virus (type 1 and type 2) and for treatment of genital warts as adjunctive therapy to podophyllin or carbon dioxide laser1. It also has certain efficacy in the treatment of AIDS and some other acquired immunodeficiency such as aged patients, cancer patients, severely burned patients, ill patients, and surgery patients3. Preclinical studies have demonstrated that isoprinosine can inhibit the growth of both DNA and RNA viruses as well as potentiate cell-mediated immune response both in vitro and in vivo4,5.
Sources
https://en.wikipedia.org/wiki/Inosine_pranobex
Waldman, R. H., and R. Ganguly. "Therapeutic efficacy of inosiplex (Isoprinosine) in rhinovirus infection. " Annals of the New York Academy of Sciences 284.1(1977):153–160.
https://www.ncbi.nlm.nih.gov/pubmed/2446760
https://www.ncbi.nlm.nih.gov/pubmed/83189
https://www.drugbank.ca/drugs/DB13156
Chemical Properties
White Solid
Uses
Different sources of media describe the Uses of 36703-88-5 differently. You can refer to the following data:
1. Isoprinosine
2. Isoprinosine is a new combination of active substances for the treatment of chronic systemic diseases such as cancer. Isoprinosine is an immunomodulator; antiviral. The ratio is between 1: 2 : 2 to 1 : 3 : 3
Biological Activity
isoprinosine is a complex of acetaminobenzoic acid, dimethylaminoisopropanol, and inosine in a 3:3:1 ratio with immunomodulatory effects.immunotherapy is the treatment of disease by inducing, enhancing, or suppressing an immune response. immunomodulatory regimens usually have fewer side effects than existing drugs, such as less potential for creating resistance when treating microbial disease.
Clinical Use
Treatment of mucocutaneous herpes simplex, genital
warts, subacute sclerosing panencephalitis
in vitro
previous study found that increasing concentrations of isoprinosine (50-400 μg/ml) could produce progressively growing inhibitory effect on hhv-1 replication. the combination of 1000 iu/ml ifn-α and isoprinosine could result in enhanced anti-hhv activity [1].
in vivo
previous study demonstrated the positive effect of isoprinosine treatment on persistent infection of balb/c mice with murine gammaherpesvirus 68. increased number of leukocytes, increased percentage of neutrophils, elevated levels of virus-neutralizing antibodies, reduced number of atypical lymphocytes and reduced virus titers were detected in the examined organs after a 14-day treatment. the positive effect of isoprinosine therapy vanished after 120-150 days [2].
Drug interactions
Potentially hazardous interactions with other drugs
None known
Metabolism
Hepatically metabolised. The major excretion
product of the inosine moiety is uric acid, while the
p-acetamidobenzoic acid and N,N-dimethylamino-
2-propanol components are excreted in the urine as
glucuronidated and oxidised products, respectively, as well
as being excreted unchanged
references
[1] majewska a, lasek w, janyst m, mynarczyk g. in vitro infibition of hhv-1 replication by inosine pranobex and interferon-α. acta pol pharm. 2016 may-jun;73(3):637-44.[2] janíková o, anicová l, briestenská k, mistríková j. the effect of isoprinosine treatment on persistent infection of balb/c mice infected with murine gammaherpesvirus 68. acta virol. 2017;61(1):32-38. doi: 10.4149/av_2017_01_32.[3] beran j, alapová e, pajdel m; isoprinosine study (ewo iso-2014/1) team. inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a phase 4, randomised, placebo-controlled, double-blind study. bmc infect dis. 2016 nov 7;16(1):648.
Check Digit Verification of cas no
The CAS Registry Mumber 36703-88-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,6,7,0 and 3 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 36703-88:
(7*3)+(6*6)+(5*7)+(4*0)+(3*3)+(2*8)+(1*8)=125
125 % 10 = 5
So 36703-88-5 is a valid CAS Registry Number.
InChI:InChI=1/C10H12N4O5.C9H9NO3.C5H13NO/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18;1-6(11)10-8-4-2-7(3-5-8)9(12)13;1-5(7)4-6(2)3/h2-4,6-7,10,15-17H,1H2,(H,11,12,18);2-5H,1H3,(H,10,11)(H,12,13);5,7H,4H2,1-3H3/t4-,6-,7-,10-;;/m1../s1
